Bioactive derivatives from the camphor laurel tree, Cinnamomum camphora, are posited to exhibit chemopreventive properties but the efficacy and mechanism of these natural products are not fully understood. We tested an essential-oil derivative, camphor white oil (CWO), for anti-tumor activity in a mouse model of keratinocyte-derived skin cancer. Daily topical treatment with CWO induced dramatic regression of premalignant skin tumors and a two-fold reduction in cutaneous squamous cell carcinomas. We next investigated underlying cellular and molecular mechanisms. In Together, these studies identify T cell-mediated tumor regression as a mechanism through which a plant-derived essential oil diminishes established tumor burden.
distillation of wood from the camphor laurel tree (Cinnamomum camphora), is marketed as a fragrance and herbal remedy with antifungal, antiseptic, and medicinal properties including circulatory stimulation, increased metabolism, and improved digestion. [2] [3] [4] CWO primarily consists of a mixture of structurally related terpenes, a class of chemical compounds composed of isoprene units with distinct aromatic qualities that plants generate for defensive purposes.
CWO's terpene constituents are widely found in natural and industrial products. These terpenes are volatile, bioactive, and readily absorbed by the skin. Abundant constituents of CWO include eucalyptol, a natural cough suppressant, and limonene, an antiseptic.
Counterintuitively, camphor is found at only trace amounts in this distillate. Interestingly, several of the purified components of CWO, or plants that contain these ingredients, are proposed to have antitumorigenic effects; however, few of these compounds have been rigorously tested in vivo for these properties. [4] [5] [6] [7] [8] [9] Terpene constituents of CWO are also common in skin-care products; however, mechanisms through which these bioactive compounds act on epithelial cells have not been identified.
Cutaneous squamous cell carcinoma (cSCC), a non-melanoma skin cancer, is the most common form of skin cancer with metastatic potential. 10 cSCC is often preceded by pre-malignant skin lesions termed actinic keratoses (AKs). 11 AKs are generally treated by fielddirected therapy; however, they can recur and convert to cSCC with metastatic potential, particularly in organ transplant recipients and patients with other risk factors such as smoking. 12, 13 Thus, there is a need for novel, non-toxic, and cost-effective therapeutics to prevent malignant conversions in high-risk patients. Remarkably, nearly 50% of all drugs approved for use in cancer since the 1940s are either natural products or derivatives, suggesting that essential oils such as CWO could be a source for developing new therapeutics. 14 To identify whether CWO has biological effects on keratinocytederived skin lesions, we employed a pre-clinical model of cSCC in mice.
Our results show that daily topical application of naturally derived CWO induces premalignant tumor regression and reduces malignant conversion to cSCC in vivo. CWO induced calcium/calcineurin mediated Nuclear Factor of Activated T cells (NFAT) translocation in keratinocytes, causing transcriptional effects that culminate in immune system activation and cytotoxic T cell-dependent tumor regression.
Finally, two purified constituents, α-pinene and d,l-limonene, recapitulated the anti-tumor effects of the essential oil. Together, these studies identify CWO as potent anti-tumor agent, establish underlying biological mechanisms and pinpoint lead compounds for further development as new treatments for cSCC.
| MATERIALS AND METHODS

| Animals
Animal use was conducted according to guidelines from the National
Institutes of Health's Guide for the Care and Use of Laboratory Animals and the Institutional Animal Care and Use Committee of Columbia
University Medical Center. Age-matched female FVB/NJ mice from Jackson labs were used in all experiments except for TRPV3 knockout mice (Jackson labs stock #010773).
| Tumor induction
Mice were shaved at age 6-7 wks with electric clippers and telogen, the resting hair cycle stage, was confirmed after 2 d. One topical application of 400 nmol DMBA in 200 μL acetone was administered, followed by 1 week of rest then twice-weekly applications of 200 μL of 10 nmol TPA in acetone. This TPA regimen ensured each mouse generated a high tumor burden by 15 wks with at least one malignant conversion before endpoint. Mice were monitored daily and euthanized when they had a tumor >20 mm in diameter, had tumor ulceration leading to loss of skin barrier, showed signs of anemia for ≥24 h, or had a gross appearance indicating distress (hunched posture, lethargy, persistent recumbence).
| Tumor classification criteria
Tumor number and location were documented weekly. A lesion was classified as precancerous based on its appearance as a non-ulcerated, fleshy pedunculated or sessile wart-like mass with a diameter in any dimension ≥2 mm. Lesions were classified as malignant SCCs when they converted to a flattened circular growth with a depressed center, or showed spontaneous ulceration. 
| Treatment paradigm
Mice assigned to the CWO or terpene groups were treated daily with topical 2.5-40% oil in acetone (wt/wt; 400 μL, applied drop-wise).
Control mice were treated with topical acetone vehicle (Veh, 400 μL).
Three to seven days after the last TPA treatment, mice were randomly assigned to CWO, terpene, or control treatment groups, matched for total precancerous lesion burden. Mice assigned to the CWO or terpene groups were treated daily with topical 2.5-40% oil in acetone (wt/wt; 400 μL applied drop-wise 
| Cell culture
Primary keratinocytes were derived from discarded human foreskin tissue using two-step enzymatic digestion. Connective tissue was removed and skin was treated overnight with dispase at 4C. Epidermis was separated and treated with 0.25% trypsin and transferred to DMEM with 10% FBS, dissociated with a pipette, filtered with a 70 μm cell strainer and grown in keratinocyte growth media (CnT07, CellNTech, Bern, Switzerland). All cells used were <5 passages and plated to 70-85% confluence. At least three independent keratinocyte donors were used in all experiments. RNA-sequencing of tumors was initiated using a published DMBA-TPA protocol as described above. Mice were treated for 6 wks and then tumors were harvested. Four pre-malignant tumors of approximately the same size per mouse were pooled (N = 3 mice per treatment). The pooled tumors were homogenized in 1 mL TRizol using an Omni International (Kennesaw, GA) homogenizer with soft tissue disposable tips. RNA extraction proceeded as above.
| Calcium imaging
RNA-Seq data have been deposited in NCBI's Gene Expression
Omnibus 17 and are accessible through GEO Series accession number GSE117557 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE117557).
Differential expression was determined using DESeq and data were filtered for genes with mean expression >5 RPKM and P > 0.05.
This resulted in 1655 dysregulated genes in skin and 293 dysregulated genes in tumors. GO analysis was performed using Cytoscape 18 with the ClueGO plugin. 19 Data were analyzed to identify significantly altered GO terms in both datasets using Enrichment/Depletion (twosided hypergeometric test with a Bonferroni step-down correction).
Data shown are GO levels 4-7 with at least two genes per cluster representing at least 4% of the genes in the cluster with GO term fusion.
| T-cell blocking
T-cell blocking antibodies were given by intraperitoneal injection 100 μg/injection on treatment days −1, 2, then once weekly until endpoint. Antibodies used were anti-mouse CD8 (Clone 2. 
| GC-MS analysis
GC-MS analysis was performed by NDE Analytical (Pleasonton, CA) using the Agilent GC-MS system 6890/5973 with a TG-624 30 m column length, 1.4 μm film thickness, 0.25 mm ID and helium carrier gas. The temperature program used was 100C for 4 min, 100-120C for 10 min, 120-220C for 6 min with a 50C/min ramp up rate. Data were matched to existing library spectra.
| Statistics
Data are expressed as mean ± SEM unless noted. Statistical analysis was performed using Graphpad (Prism V5, San Diego, CA). Outliers were identified using Grubbs method with Alpha = 1 × 10
. Graphs showing the number of malignant conversions were fitted using the Boltzmann sigmoidal equation:
| CWO induces cutaneous tumor regressions
To test whether CWO possesses anti-tumor activity in vivo, a two-step chemical carcinogenesis model of cSCC was employed in mice. 21 Tumor formation was initiated by a single topical application of 7,12-Dimethylbenz[a]anthracene (DMBA) to the dorsal skin of mice, followed by twice weekly applications of the tumor promotor 12-O-tetradecanoylphorbol-13-acetate (TPA) for 12 weeks ( Figure 1A ). In this model, premalignant lesions called papillomas form, up to 50% of which will convert to cSCCs, depending on mouse strain and dosage of initiator and promotor. [21] [22] [23] Chemically induced tumors in mice have both histological and molecular profiles that recapitulate SCCs in humans. 21, 24 After papillomas developed, mice were randomly assigned to one Figure S3I and J). Thus, we conclude that CWO has robust antitumor activity on keratinocyte-derived lesions in vivo.
| CWO induces calcium/calmodulin-dependent NFAT signaling in keratinocytes
To define mechanisms that might underlie this striking reduction in tumor burden, we sought to uncover molecular pathways through which CWO exerts bioactive effects on keratinocytes. We reasoned that CWO might activate NFAT in keratinocytes. In a low-calcium environment, this transcription factor localizes to the cytoplasm. In response to cytoplasmic calcium signaling, NFAT is dephosphorylated by calcineurin, a calcium/calmodulin-dependent phosphatase, which allows NFAT to enter the nucleus and directs target gene expression. [25] [26] [27] Three lines of evidence focused our attention on NFAT signaling. First, previous studies have shown that terpenes activate calcium signaling in mammalian cells in vitro, [28] [29] [30] which is an essential step in NFAT activation. Second, inhibition of calcineurin with cyclosporine A (CSA) promotes cSCC in humans and animal models, underscoring the role of calcineurin/NFAT in SCC pathogenesis. 31 Finally, CSA regulates the cell cycle in SCC keratinocytes in vitro, suggesting that calcineurin/NFAT signaling has direct effects on keratinocytes relevant to cancer biology. 32, 33 We first asked whether CWO induces calcium signaling. Normal human epidermal keratinocytes were loaded with the ratiometric calcium indicator Fura-2 AM and responses to CWO application were monitored with live-cell imaging. CWO induced rapid increases in cytoplasmic calcium in a dose-dependent manner (Figure 2A-C) . In many cases, calcium waves were observed in individual keratinocytes (Sup. Figure S4 ), an activation pattern that induces the calcium/ calcineurin-dependent transcription factor NFAT to translocate to the nucleus and direct expression of target genes. [25] [26] [27] To test the hypothesis that NFAT is activated downstream of CWO treatment in keratinocytes, we analyzed nuclear translocation of NFATc1, an isoform with well documented activity in human keratinocytes ( Figure 2D ). [34] [35] [36] [37] Keratinocytes treated in vitro with 0.02-0.04% CWO displayed significant translocation of NFATc1 without compromising cell viability (Sup. Figure S5 ). This effect was completely eliminated by pre-treatment with CSA, indicating that NFAT translocation was dependent on calcium/calcineurin signaling ( Figure 2E ). Thus, we conclude that CWO induces NFAT translocation through calcium/calcineurin signaling in keratinocytes.
NFAT activity has context-dependent effects on keratinocyte proliferation, both maintaining stem cell quiescence and inducing keratinocyte proliferation. 34, [37] [38] [39] We postulated that CWO might also alter the cell cycle through NFAT activity. We noted that CWO application induces mild thickening of the mouse epidermis adjacent to experiments with >1200 cells per replicate; P < 0.05 One-way ANOVA, Bonferroni post-hoc comparison with Veh). E, Cells were pre-treated for 1 h with CSA or vehicle followed by a 30-min treatment with 0.04% CWO or vehicle. NFAT localization after incubation with Veh/Veh, Veh/ 0.04% CWO (Left), 1 μM CSA/0.04% CWO, and 1 μM CSA/Veh (Right). Two-way ANOVA found a significant effect of CWO (P < 0.0001) and CSA (P < 0.001). Bonferroni post-hoc comparison revealed a significant difference between Veh/Veh and Veh/CWO samples that was abolished with CSA pre-treatment. N = 10-11 experiments/group. One statistical outlier (as determined by Grubbs' test) was removed from both CSA/V and CSA/CWO groups. F, Mice were treated 2x with CSA or Veh every 24 h followed by one application of CWO or Veh. 23 h later, mice were given a single injection of EdU. After 1 h, keratinocytes were collected. G, Representative flow gates. The percentage of EdU+ basal keratinocytes (α6-integrin +) were quantified. H, CWO induced a significant increase in basal keratinocyte proliferation. Two-way ANOVA P CSA < 0.001, P CWO < 0.0001. Bonferonni post hoc analysis revealed a significant difference between Veh/CWO and Veh/Veh treatment groups, which was abolished by CSA pre-treatment. N = 9-10 animals/group, one statistical outlier was removed from the CSA/CO group. *P < 0.05, ***P < 0.001, ****P < 0.0001, Red lines indicate group mean values. [Color figure can be viewed at wileyonlinelibrary.com] was enhanced two-fold by CWO treatment and this effect was blocked by CSA treatment (Figure 2G and H) . We conclude that CWO induces calcium/calcineurin/NFAT signaling that mediates biological effects on keratinocytes in vivo.
Given that CWO induces calcium signaling and proliferation in keratinocytes, we hypothesized that it might work through TRPV3, a calcium channel which is expressed in keratinocytes and is activated by camphor and related terpenes. 30, 41 To test whether TRPV3 is required for CWO's effects in the skin, we performed in vivo proliferation assays on TRPV3 knockout animals and wild-type littermates (Figure 3 ).
TRPV3 disruption had no effect on CWO-meditated proliferation; therefore, we conclude that the effects of CWO are not TRPV3 dependent.
| CWO treatment induces immune-dependent tumor clearance
We next took an unbiased, genome-wide approach to identify genetic Figure S7B) ; however, CD4+ cells were present at sacrificing, indicating that this population was not fully depleted by antibody treatment (Sup. Figure S7C ). Collectively, these data suggest that CWO-mediated tumor regression depends on CD8+ cytotoxic T cells.
| Identification of CWO's active ingredients and effective concentrations
Finally, we sought to determine active compounds in CWO that stimulate tumor regression. As a natural plant derivative, CWO's mixture of terpenes varies depending on terroir. 2 Using gas FIGURE 3 Camphor-oil's biological effects on keratinocytes is independent of TrpV3. A, TrpV3 mutant and age-matched wild-type mice were treated with CWO or vehicle control for 5 days. Mice were then given a 1-h pulse of EdU and keratinocytes were collected and analyzed as in Figure 2 . B, CWO induced a significant increase in basal keratinocyte proliferation; however, there was no significant effect of TRPV3 knockout on proliferation (N = 4-5 mice per group; two-way ANOVA, non-significant genotype effect, treatment effect: P < 0.0001; Bonferroni post hoc analysis: **P < 0.01,***P < 0.001) chromatography-mass spectrometry (GC-MS), we found that many structurally related terpenes were present in CWO, with eucalyptol and d,l-limonene being the most abundant constituents ( Figure 5A ). As expected due to distillation, camphor was identified only in trace quantities in CWO and is thus not expected to be an active ingredient. Figure S8) . Thus, we conclude that d,l-limonene and/or α-pinene likely mediate the antitumor effects of CWO.
We next sought to identify effective concentrations of terpenes for tumor reduction in vivo. Tumor-bearing mice were split into matched groups and treated daily with a range of concentrations of CWO, d,l-limonene, or α-pinene (0-40%; N = 5 mice per group). CWO was rapidly effective at high concentrations (40%; Figure 5B ), with significant reduction in tumor burden achieved within 1 week ( Figure 5C ). In pilot studies, 40% solutions of either d,l-limonene or α-pinene produced marked skin irritation or toxicity; thus, these chemicals were applied up to 20% ( Figure   5D ). d,l-Limonene produced the largest reduction in skin tumors at 20%, which was apparent 2 weeks after the start of treatment ( Figure 5D and E). By contrast, 2.5% α-pinene resulted in significant reductions in tumor burden ( Figure 5F and G).
Interestingly, higher concentrations of α-pinene did not reduce FIGURE 4 CWO-induced tumor regression requires cytotoxic T cells. A, Epidermis and tumors treated with CWO or vehicle were analyzed with RNA sequencing and results were compared (left). Epidermis was treated with a single application of CWO, tumors were collected after 6 wks of treatment. In skin, 1577 genes were differentially enriched, 215 in tumors, and 77 in both groups with CWO treatment. GO-analysis of terms enriched with CWO treatment in both papillomas and keratinocytes were analyzed (right) and compared to identify common pathways affected in both groups. Terms consistent with immune activation are in red font. B, Tumors were induced as before, mice were split into matched cohorts, then injected with T-cell blocking or isotype control antibodies on Day −1, 2 and then 1x weekly. C, CD8 blocking antibody reversed the effects of CWO treatment (N = 7 mice/group, two-way ANOVA identified a significant interaction between time and treatment group (P < 0.05), and significant effects of both time and treatment group (P < 0.0001). One-way ANOVA split by treatment group, P < 0.01, Tukey's multiple comparison test *P < 0.05, ** < 0.01. [Color figure can be viewed at wileyonlinelibrary.com] FIGURE 5 CWO constituents partially recapitulate the effects of CWO. A, Gas-chromatography mass spectrometry analysis of CWO. Percentage of constituent present in CWO is shown on the pie chart and the percentage match to reference is shown in parentheses. One compound did not match well to reference. B-G, Dose-response studies to identify effective concentrations of CWO and constituents in reducing tumor burden. Tumors were induced as before and mice were split into matched groups (N = 5 mice/group). Mice were treated for 6 weeks with CWO or constituent terpenes (0-40%). B, D, F show the number of lesions/mouse at week 0 (black line) and 6 weeks (teal line) for each concentration tested. C, E, F show % of tumors remaining for vehicle (black line) and the optimal concentration of compound (teal line). All data were analyzed with two-way ANOVA with Bonferroni post-hoc. Significance of group P-values is denoted on side of graph, and post-hoc differences at each week are noted above the time point. *P < 0.05, #P < 0.01, ΩP < 0.001,Ф P < 0.0001. B, CWO showed a dose-dependent effect and 40% CWO was most effective. C, 40% CWO caused a significant effect after 1 week of treatment, and was significantly different from vehicle treatment. D, d,l-Limonene showed a slight dose-dependent response, with 20% causing the greatest reduction in tumor burden. E, 20% d,l-Limonene caused a significant reduction in tumor burden compared to vehicle. F, α-Pinene was maximally effective at 2.5% concentration. G, 2. cytes. 35, 36 In the hair cycle, NFAT signaling promotes bulge stem cell quiescence by inhibiting the cell cycle regulator CDK4. [34] [35] [36] By contrast, overactivation of NFAT in epidermal cells promotes keratinocyte hyperproliferation. 37 The latter report is consistent NFAT activation in keratinocytes. 51 TSLP is well known for having a role in promoting allergic inflammation 52 and, when released from keratinocytes, can promote the atopic march that proceeds to asthma development. 53 Interestingly, allergic inflammation can reduce risk of certain cancers while increasing the risk for others. 54 Several intriguing studies have shown that TSLP has an additional role in stimulating antitumor immunity through CD4+ and CD8+ T-cell activation. [55] [56] [57] TSLP released from keratinocytes can directly stimulate CD4+ T H activation and recruitment of cytotoxic CD8+ T cells to tumors.
Interestingly, we found that TSLP mRNA was upregulated in keratinocytes treated with CWO, indicating that TSLP release from keratinocytes could promote CD8+ T cell recruitment to tumors, and thus contribute to CWO-mediated tumor regression.
Along with effects on keratinocytes, CWO could act directly on T cells, either through resident populations in skin or through systemic effects. [58] [59] [60] Indeed, NFAT isoforms have been most heavily studied for their effects on T cells. 61 Upon T cell activation, nuclear NFAT proteins complex with AP1 transcription factors to stimulate gene expression linked to activation. NFATc1, in particular, is necessary for cytotoxic CD8+ T cell activation, by regulating effector memory T cell expansion and gene expression associated with cytotoxicity. 62, 63 CD8+ T cells that lack NFAT have severely impaired cytotoxicity against A20J tumor cells and Listeria infection. 62 Indeed, low NFAT expression correlates with poor prognosis in non-small cell lung cancer. 63 Collectively, this study identifies CWO as a novel activator of NFAT signaling and calcium/calcineurin-mediated antitumor immunity. Organ transplant recipients that receive long-term treatment with calcineurin inhibitors are at dramatically increased risk for SCC, 32, 34, 38, 39, 64 arguing that NFAT activators might be used to reduce epithelial tumor risk. As these studies investigated the efficacy of CWO and terpene compounds after tumor induction, future studies are needed to determine whether these compounds can also act as a preventive to reduce the development of pre-cancerous lesions. This raises the possibility that CWO could serve as an effective topical treatment to prevent the progression of keratinocyte-derived lesions. 
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